Rasagiline Tablets 0.5mg, 30-count bottle, Rx only, Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A., NDC 0378-1270-93
Published September 27, 2023 · Recall initiated: August 2, 2023
Summary
FDA records drug Class II recall D-1171-2023, published September 27, 2023 and initiated August 2, 2023. Recalling firm: Aurobindo Pharma USA Inc.; Status: Terminated; Reported quantity: 9,890 bottles; Lot: Lot #: 3112444, Exp 8/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed dissolution specifications - results obtained were below spec average.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Aurobindo Pharma USA Inc.
- Distributor
- USA nationwide
- Lot
- Lot #: 3112444, Exp 8/2023
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAClorazepate Dipotassium Tablets, USP, 7.5 mg, a) 100 tablets per bottle, NDC 13107-283-01, b) 500 tablets perMay 15, 2024
- FDAClorazepate Dipotassium Tablets, USP, 3.75 mg, a) 100 tablets per bottle, NDC 13107-282-01 b) 500 tablets perMay 15, 2024
- FDABD ChloraPrep Clear, 2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA) SterileSeptember 27, 2023
- FDACequa (cyclosporine ophthalmic solution) 0.09%, 60 Single-Use Vials (6 pouches x 10 single-use vials (0.25 mLSeptember 27, 2023
- FDARufinamide Tablets, USP 400 mg, packaged in 120-count bottle, Rx only, Distributed by: Aurobindo Pharma USA,August 30, 2023
- FDARufinamide Tablets, USP 200 mg, packaged in 120-count bottle, Rx only, Distributed by: Aurobindo Pharma USA,August 30, 2023
Questions about this recall
Was Rasagiline Tablets 0.5mg, 30-count bottle, Rx only, Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A., NDC 0378-1270-93 recalled?
Yes. FDA published recall D-1171-2023 on September 27, 2023. Reported hazard: Failed dissolution specifications - results obtained were below spec average.
What should I do if I have this product?
Voluntary: Firm initiated · Letter